The company’s ANDA product is a generic version of UCB’s Neupro, which is designed to treat signs and symptoms of idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs
The company has also secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product. The product is
With this acquisition, Roche is eyeing to expand its offerings and bolster its presence in the treatment of deadly lung diseases. The company’s offer of $74 a share
The firms will evaluate the use of Advaxis’ Lm-LLO cancer immunotherapy, ADXS-PSA, in combination with Merck’s pembrolizumab in the Phase I/Phase II trial. The trial will assess the
This patent, when issued, will be valid until at least 2026. Additional patents claiming the BL-7010 composition and uses thereof are granted or pending in the US, Europe,
In the Phase 2a trial, all three doses of CCH (low (0.06mg), mid (0.48mg) and high (0.84mg)) showed an improvement in the appearance of cellulite as measured by
These patents have issued over the last several months from the intellectual property licensed by Dicerna from the City of Hope (COH) estate in November 2007. The newly
Under the new EMSA, Sucampo receives a new, lower price for certain components of or finished product of lubiprostone globally, except for the United States and Canada until
Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2
"These data are important for people suffering from moderate-to-severe plaque psoriasis, as up to 41 percent of those treated with ixekizumab were able to achieve clear skin at
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.